sponsored
PatientsVille.com Logo

PatientsVille

Klaricid Medical Research Studies

Up-to-date List of Klaricid Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Klaricid Medical Research Studies

Rank Status Study
1 Recruiting Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: Dexamethasone;   Drug: Clarithromycin;   Drug: Lenalidomide
Outcome Measures: Response to Car-BiRD treatment.;   Event free survival
2 Recruiting Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane
Condition: Preterm Premature Rupture of Membrane
Interventions: Drug: Cefazolin;   Drug: Clarithromycin
Outcome Measures: Neonatal composite morbidity;   infantile neurologic outcome
3 Unknown  Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Condition: Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: clarithromycin;   Drug: Pomalidomide
Outcome Measure: response rate
4 Recruiting Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Procedure: stem cell;   Drug: Dexamethasone;   Drug: Clarithromycin
Outcome Measures: overall response rate;   safety analyses;   overall survival;   progression free survival
5 Recruiting Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy
Condition: Eradication Rates of the Two Regimens
Interventions: Drug: D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole);   Drug: D1-D14: (lansoprazole + clarithromycin + amoxicillin)
Outcome Measures: Eradication rate according to Intention to treat (ITT) and per-protocol (PP) analysis;   Incidence of adverse effects
6 Recruiting 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication
Condition: Helicobacter Pylori Infection
Intervention: Drug: PPI, amoxicillin, metronidazole and clarithromycin
Outcome Measures: "Intention to treat" eradication rates;   " Per protocol" eradication rate;   Treatment compliance;   Number of participants with adverse events
7 Recruiting Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy
Condition: Helicobacter Pylori Infection
Interventions: Drug: pantoprazole, amoxicillin, clarithromycin, metronidazole;   Drug: pantoprazole, amoxicillin, clarithromycin, metronidzole
Outcome Measure: Comparison of the eradications rates of sequential therapy versus concomitant therapy of treatment of Helicobacter pylori infection in Korea.
8 Recruiting Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis
Condition: Bronchopulmonary Dysplasia
Interventions: Drug: clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia;   Drug: Saline
Outcome Measures: Bronchopulmonary dysplasia;   Overall survival
9 Unknown  Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalomid;   Drug: lenalidomide;   Drug: clarithromycin;   Drug: dexamethasone
Outcome Measure: effect of drug combination on multiple myeloma
10 Recruiting Treatment of Mycobacterium Xenopi Pulmonary Infection
Condition: Atypical; Mycobacterium, Pulmonary, Tuberculous
Interventions: Drug: Clarithromycin;   Drug: Moxifloxacin
Outcome Measures: Sputum conversion at 6 months under three antibiotics treatment (Rifampin, ethambutol and a third drug clarithromycin or moxifloxacin);   Sputum conversion at 3, 6, 9 and 12 months of treatment in the two different arms (clarithromycin containing regimen versus moxifloxacin containing regimen;   Clinical and radiological outcome after 3, 6 and 12 months of treatment according to the treatment arm;   Mortality after 12 months of treatment in the two compared regimen;   Gastrointestinal toxicity and hematotoxicity after 1- 3- 6- 9- 12- months of treatment
11 Recruiting Pharmacokinetic Study of Clarithromycin in Very Low Birth Weight (VLBW)
Conditions: Very Low Birth Weight Infant;   Ureaplasma/Mycoplasma Positive
Intervention: Drug: Clarithromycin
Outcome Measure: pharmacokinetics
12 Recruiting Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene
Conditions: Anovulation;   Disorder Due Cytochrome P450 CYP2D6 Variant;   Cytochrome P450 CYP3A Enzyme Deficiency
Interventions: Drug: Clomiphene;   Drug: clomiphene and paroxetine;   Drug: clomiphene and clarithromycin
Outcome Measures: Area under the plasma concentration versus time curve (AUC)of clomiphene;   Peak Plasma Concentration (Cmax)of Clomiphene;   Clearance of Clomiphene;   Metabolomic;   Tmax of clomiphene;   Pharmacogenomics
13 Recruiting Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma
Condition: Lymphoma
Intervention: Drug: clarithromycin, oral, high dose
Outcome Measure: assessment of responses
14 Unknown  Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
Condition: Dyspepsia
Intervention: Procedure: gastroscopic examination
Outcome Measures: Incidence of H. pylori Clarithromycin resistance gene;   Characteristic of H. pylori clarithromycin resistant gene mutation
15 Recruiting Concomitant Therapy of H. Pylori
Condition: Gastritis, Gastric Ulcer, and Duodenal Ulcer
Intervention: Drug: amoxicillin, clarithromycin, metronidazole, rabeprazole
Outcome Measure: Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori
16 Recruiting Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection
Condition: Helicobacter Pylori Infection
Interventions: Drug: 7-day quadruple therapy;   Drug: 10-day sequential therapy;   Drug: 7-day standard triple therapy
Outcome Measure: eradication rate
17 Recruiting RCT: Triple vs Sequential vs Concomitant Therapy H Pylori
Condition: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Drug: 10 day triple therapy;   Drug: 10 day sequential therapy;   Drug: 10 day concomitant therapy
Outcome Measure: H pylori eradication rate
18 Recruiting A Study of LY2835219 in Participants With Cancer
Conditions: Neoplasm;   Neoplasm Metastasis
Interventions: Drug: LY2835219;   Drug: Clarithromycin
Outcome Measures: Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY2835219;   Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY32835219
19 Recruiting WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8
Condition: Mycobacterium Ulcerans Infection
Interventions: Drug: Clarithromycin Extended Release;   Drug: Streptomycin intramuscular injection
Outcome Measures: healing without recurrence and without excision surgery;   Recurrence rate within 12 months of treatment initiation;   Rate of treatment failure within 12 months of treatment initiation;   Rate of paradoxical response within 12 months of treatment initiation;   Proportion of patients with reduction in lesion surface area within 12 months of treatment initiation;   Time taken for complete lesion healing within 12 months of treatment initiation;   Proportion (%) of patients with complete healing without additional surgery or relapse;   Interval between healing and recurrence;   Proportion of each type of surgery within 12 months of treatment initiation;   Time from treatment initiation to surgery if any;   Proportion of patients with residual functional limitations;   Treatment discontinuation and compliance rates;   Incidence of all adverse effects (AEs) within 12 months of treatment initiation
20 Not yet recruiting CYP3A4 Induction and Mineral Homeostasis
Condition: Vitamin D and Calcium Homeostasis
Interventions: Drug: Rifampin;   Drug: Clarithromycin;   Other: Grapefruit Juice
Outcome Measures: 1, 25(OH) D3 Vitamin D;   25(OH) D3 Vitamin D;   Parathyroid Hormone;   Osteocalcin;   Calcium, total;   Calcium, ionized;   Calcium;   Phosphate

These studies may lead to new treatments and are adding insight into Klaricid etiology and treatment.

A major focus of Klaricid research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Klaricid